Loading
LZTR1 (Leucine-zipper-like transcriptional regulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Prostate cancer, Endometrial cancer and 5 more.
Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras GTPases (M-Ras/MRAS, K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) and Ras-like protein RIT1. Acts as a negative regulator of RAS-MAPK signalling by controlling Ras levels and decreasing Ras association with membranes.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes genetic literature 0.38, literature 0.90, genetic association 0.64, somatic mutation 0.94, animal model 0.37). IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Glioblastoma Multiforme, Hepatocellular Carcinoma, Prostate Adenocarcinoma, Endometrial Carcinoma.
In plain words · LZTR1 (Leucine-zipper-like transcriptional regulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Prostate cancer, Endometrial cancer and 5 more.
LZTR1 (Leucine-zipper-like transcriptional regulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Prostate cancer, Endometrial cancer and 5 more.
Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras GTPases (M-Ras/MRAS, K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) and Ras-like protein RIT1.
No product in this corpus aims at LZTR1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA LZTR1: RNA low tissue specificity; no normal tissue stained high; highest cancer staining endometrial cancer (1 of 12 high). Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Hepatocellular carcinoma, Prostate cancer, Endometrial cancer, Skin cancer (all types), Lung cancer (all types), Breast cancer (all types), Brain and spinal cord tumours (all types)); Open Targets associates it with 3 specific cancer types at or above 0.5 (schwannomatosis, LZTR1-related schwannomatosis, hereditary neoplastic syndrome). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q8N653; CIViC gene LZTR1; IntOGen LZTR1; Human Protein Atlas LZTR1 tissue; Open Targets ENSG00000099949 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Kurahashi et al, Hum. Mol. Genet, 1995, "Isolation and characterization of a novel gene deleted in DiGeorge syndrome". Source.
Sources: HGNC HGNC:6742 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8N653 (protein name, function text, keywords and locations (REST API)); CIViC gene LZTR1 (2 evidence items, 0 assertions, 2 variants; diseases: Schwannomatosis (GraphQL API, CC0)); Open Targets ENSG00000099949 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: melanoma 0.55, skin cancer 0.57, breast cancer 0.51, lung cancer 0.52 (GraphQL API, CC0)); IntOGen LZTR1 (driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates ubiquitination of Ras GTPases (M-Ras/MRAS, K-Ras/KRAS, N-Ras/NRAS and H-Ras/HRAS) and Ras-like protein RIT1. Acts as a negative regulator of RAS-MAPK signalling by controlling Ras levels and decreasing Ras association with membranes. Location: Endomembrane system; Recycling endosome; Golgi apparatus (UniProt). Locus 22q11.21 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high; medium in Appendix, Breast, Colon, Duodenum, Epididymis, Gallbladder and more.
Medium only: melanoma, prostate cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"LZTR1" OR ABSTRACT:"LZTR1" OR TITLE:"leucine zipper like post translational regulator 1" OR ABSTRACT:"leucine zipper like post translational regulator 1" OR TITLE:"Leucine-zipper-like transcriptional regulator 1" OR ABSTRACT:"Leucine-zipper-like transcriptional regulator 1" OR TITLE:"LZTR-1" OR ABSTRACT:"LZTR-1" OR TITLE:"BTBD29" OR ABSTRACT:"BTBD29") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LZTR1, not a curated reading list.